%20on%20arm.jpg)
liraglutide
Liraglutide, sold under the brand name Victoza among others, is an anti-diabetic medication used to treat type2 diabetes, and chronic obesity. It is a second-line therapy for diabetes following first-line therapy with metformin. Its effects on long-term health outcomes like heart disease and life expectancy are unclear. It is given by injection under the skin.
Key facts
- Drug.C
- 172
- Drug.H
- 265
- Drug.image
- Liraglutide cartoon 4APD.png
- Drug.image_class
- bg-transparent
- Drug.image2
- Liraglutide ball-and-stick 4APD.png
- Drug.image_class2
- bg-transparent
- Drug.caption
- NMR structure of liraglutide. PDB entry
- Drug.tradename
- Victoza, others
- Drug.MedlinePlus
- a611003
- Drug.DailyMedID
- Liraglutide
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- Subcutaneous
- Drug.ATC_prefix
Article
16 sectionsContents
- Medical uses
- Type 2 diabetes
- Obesity
- Adverse effects
- Thyroid cancer
- Pancreatitis
- Suicidal behavior and ideation
- Pharmacodynamics
- Pharmacokinetics
- Society and culture
- Brand names
- Marketing
- Controversy
- History
- Research
- References
Liraglutide, sold under the brand name Victoza among others, is an anti-diabetic medication used to treat type2 diabetes, and chronic obesity. It is a second-line therapy for diabetes following first-line therapy with metformin. Its effects on long-term health outcomes like heart disease and life expectancy are unclear. It is given by injection under the skin.
Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) also known as incretin mimetics. It works by increasing insulin release from the pancreas and decreases excessive glucagon release.